Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer’s Disease by Marcus O. W. Grimm et al.
AGING NEUROSCIENCE
REVIEW ARTICLE
published: 23 December 2013
doi: 10.3389/fnagi.2013.00098
Neprilysin and Aβ clearance: impact of the APP
intracellular domain in NEP regulation and implications in
Alzheimer’s disease
Marcus O.W. Grimm1,2,3*, Janine Mett 1, Christoph P. Stahlmann1,Viola J. Haupenthal 1,Valerie C. Zimmer 1
andTobias Hartmann1,2,3
1 Experimental Neurology, Saarland University, Homburg, Saar, Germany
2 Neurodegeneration and Neurobiology, Saarland University, Homburg, Saar, Germany
3 Deutsches Institut für DemenzPrävention, Saarland University, Homburg, Saar, Germany
Edited by:
Roxana Octavia Carare, University of
Southampton, UK
Reviewed by:
Roxana Octavia Carare, University of
Southampton, UK
Anthony J. Turner, University of
Leeds, UK
*Correspondence:
Marcus O.W. Grimm, Experimental
Neurology, Saarland University,
Kirrbergerstr. 1, Building 90, 66421
Homburg, Saar, Germany
e-mail: marcus.grimm@uks.eu
One of the characteristic hallmarks of Alzheimer’s disease (AD) is an accumulation of amy-
loid β (Aβ) leading to plaque formation and toxic oligomeric Aβ complexes. Besides the
de novo synthesis of Aβ caused by amyloidogenic processing of the amyloid precursor
protein (APP), Aβ levels are also highly dependent on Aβ degradation. Several enzymes are
described to cleave Aβ. In this review we focus on one of the most prominent Aβ degrad-
ing enzymes, the zinc-metalloprotease Neprilysin (NEP). In the first part of the review we
discuss beside the general role of NEP in Aβ degradation the alterations of the enzyme
observed during normal aging and the progression of AD. In vivo and cell culture experi-
ments reveal that a decreased NEP level results in an increased Aβ level and vice versa.
In a pathological situation like AD, it has been reported that NEP levels and activity are
decreased and it has been suggested that certain polymorphisms in the NEP gene result in
an increased risk for AD. Conversely, increasing NEP activity in AD mouse models revealed
an improvement in some behavioral tests.Therefore it has been suggested that increasing
NEP might be an interesting potential target to treat or to be protective for AD making it
indispensable to understand the regulation of NEP. Interestingly, it is discussed that the
APP intracellular domain (AICD), one of the cleavage products of APP processing, which
has high similarities to Notch receptor processing, might be involved in the transcriptional
regulation of NEP. However, the mechanisms of NEP regulation by AICD, which might be
helpful to develop new therapeutic strategies, are up to now controversially discussed and
summarized in the second part of this review. In addition, we review the impact of AICD
not only in the transcriptional regulation of NEP but also of further genes.
Keywords:Alzheimer’s disease,Abeta degradation, neprilysin,AICD, amyloid beta, transcriptional regulation,Abeta
clearance
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is one of the most common neurodegen-
erative disorders of the central nervous system. Currently more
than 35 million people are affected worldwide and the number
of affected people is estimated to double every 20 years leading to
more than 115 million AD cases in the year 2050 (AD International,
2013). It is characterized by a degeneration of neurons in multiple
brain regions, mainly the cortical and subcortical areas and hip-
pocampus, leading to a loss of cognitive brain functions, memory
impairment,and often to behavioral and physiological changes like
apathy and depression. Characteristic histopathological hallmarks
are intracellular neurofibrillary tangles composed of a hyperphos-
phorylated form of the microtubule-associated protein tau and
extracellular β-amyloid plaques in brain tissue (Grundke-Iqbal
et al., 1986; Selkoe, 2004; Binder et al., 2005). Major components of
the β-amyloid deposits are hydrophobic amyloid-β-peptides (Aβ),
which are 38–43 amino acids (aa) long fragments derived from
proteolytic processing of the amyloid precursor protein (APP)
(Glenner and Wong, 1984; Masters et al., 1985; Aguzzi and Haass,
2003).
Most of the AD cases belong to the sporadic form of the disease
with an onset after the age of 65 (late onset AD, LOAD). Less than
5% of all AD cases are genetically based (familial AD, FAD) due to
mutations in the genes encoding for APP or presenilin1 (PS1) and
presenilin2 (PS2), proteins involved in the proteolytic cleavage of
APP, leading to an earlier age of onset (Scheuner et al., 1996; Hardy,
1997). According to the amyloid cascade hypothesis, the excessive
accumulation and aggregation of the 4 kDa Aβ-peptide is regarded
to be central in the pathogenesis of AD, initiating cellular cascades
leading to synaptic loss and neuronal injury (Hardy and Higgins,
1992; Hardy and Selkoe, 2002). Especially an increase in Aβ42
(indicating 42 aa) is reported to trigger the disease process due to
its high tendency to aggregate. Most of the FAD-linked mutations
lead to an increase in total Aβ levels or the ratio of Aβ42/Aβ40
resulting in an aggressive and early occurring pathology (Kowal-
ska, 2004; Duering et al., 2005). Accumulating evidence suggests
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that oligomeric Aβ species including dimers and trimers (Cleary
et al., 2005; Shankar et al., 2007), small diffusible oligomers (Lam-
bert et al., 1998), donut-like annular oligomers (Lashuel et al.,
2002), and large amylospheroids (Hoshi et al., 2003) represent the
most toxic forms of the peptide causing impaired synaptic and
neuronal functions (Haass and Selkoe, 2007; Walsh and Selkoe,
2007).
The Aβ levels in brain, are not only dependent on the de novo
synthesis by APP processing, but also by its elimination via differ-
ent mechanisms including its proteolytic degradation, transport
processes, cell mediated clearance, and its deposition into insol-
uble aggregates. While enhanced Aβ generation and a shift in
the Aβ40/42 ratio have been shown to be associated with FAD,
a diminished Aβ clearance has been long hypothesized to pre-
dominate in LOAD (Tanzi et al., 2004; Hama and Saido, 2005).
Indeed, recently a study by Mawuenyega et al. (2010) confirmed
a significant impairment in the clearance of cerebrospinal fluid
(CSF) Aβ in LOAD patients.
APP AND THE GENERATION OF Aβ
THE APP FAMILY OF PROTEINS
Amyloid precursor protein is a ubiquitously expressed type I inte-
gral transmembrane protein consisting of a large ectodomain, one
single transmembrane domain, and a short intracellular tail (Kang
et al., 1987; Dyrks et al., 1988). It belongs to a small gene fam-
ily including the APP-like proteins 1 and 2 (APLP1 and APLP2)
in mammals (Sprecher et al., 1993; Wasco et al., 1993), APL-
1 in C. elegans, APPL in D. melanogaster, and APPa and b in
zebrafish (Musa et al., 2001). While APP and APLP2 are ubiqui-
tously expressed, APLP1 expression is restricted to neurons (Tanzi
et al., 1988; Slunt et al., 1994; Lorent et al., 1995). The gene encod-
ing for human APP is located on chromosome 21 and contains 18
exons (Yoshikai et al., 1990). Alternative splicing of exons 7 and
8 generates APP mRNAs encoding for several isoforms, mainly
APP770, APP751, and APP695 (referring to length in aa) with the
latter being the major neuronal species (Sandbrink et al., 1994).
While single knockout (KO) of one of the APP family members
results only in viable mild phenotypes, APP/APLP2 double KO
animals are perinatal lethal showing for example severe deficits
in neuromuscular junctions (Wang et al., 2005a). Mice genetically
deleted of all three APP gene family members show a neuronal
ectopy in forebrain resembling the human type 2-lissencephaly,
which also leads to animal death short time after birth (Herms
et al., 2004). These severe phenotypes indicate important, partially
overlapping physiological functions of APP, APLP1, and APLP2 in
the mammalian nervous system (Aydin et al., 2012).
PROTEOLYTIC PROCESSING OF APP
Proteolytic processing of APP occurs via two different cleavage
pathways and shows large homologies to the proteolytic processing
of the Notch receptor as demonstrated in Figure 1.
In the case of the amyloidogenic processing pathway,APP is first
cleaved within the extracellular domain by the transmembrane
aspartyl protease BACE1 (β-site APP cleaving enzyme 1) shedding
off the soluble ectodomain sAPPβ and generating the membrane-
tethered C-terminal fragment (CTF) C99 (termed according to
length in aa) (Vassar et al., 1999). In the case of the predominant
non-amyloidogenic APP cleavage cascade the soluble ectodomain
sAPPα and the C-terminal membrane-spanning stub C83 are gen-
erated by the activity of the α-secretases, members of the ADAM (a
disintegrin and metalloprotease) protein family (Lammich et al.,
1999; Hooper and Turner, 2002). The α-secretase cleavage site
is located at position 16 within the Aβ sequence, precluding the
generation of Aβ in the non-amyloidogenic pathway. The two
alternative pathways are located in different subcellular compart-
ments: while non-amyloidogenic APP processing, which is the
major pathway of APP cleavage in all cells, takes place at the plasma
membrane (Parvathy et al., 1999; Ehehalt et al., 2003), the amy-
loidogenic APP processing by β-secretase cleavage takes place in
endosomes having a more acidic pH, which is also the pH opti-
mum of BACE1 mediated APP turn over (Grbovic et al., 2003;
Carey et al., 2005; Rajendran et al., 2006).
The APP-CTFs are subsequently cleaved by γ-secretase liberat-
ing either the non-toxic peptide p3 (from C83) or Aβ (from C99)
and the APP intracellular domain (AICD), which is discussed to
regulate the expression of several genes, into the cytosol (Haass
et al., 1992; Passer et al., 2000; Cao and Sudhof, 2004). The γ-
secretase complex consists of at least four proteins, the proteins PS1
or PS2 as catalytic core, nicastrin,Aph (anterior pharynx defective)
1a or b, and presenilin enhancer 2 (PEN2) (Grimm et al., 2002;
Baulac et al., 2003; Edbauer et al., 2003; Kimberly et al., 2003). It
cleaves its substrates within the hydrophobic environment of the
membrane, a process frequently involved in important signaling
pathways and termed regulated intramembrane proteolysis (RIP)
(Lichtenthaler et al., 2011). As γ-secretase cleavage can take place
at different positions, Aβ and AICD peptides vary in length. Since
the major produced Aβ species end at position 40 or 42 (Haass
et al., 1992; Seubert et al., 1992; Roher et al., 1993; Iwatsubo et al.,
1994), one can assume that AICD should begin at position 41 or 43
(aa numbers referring to the Aβ sequence). Contrary, most of the
generated AICD seems to begin close to aa position 50 (Gu et al.,
2001; Yu et al., 2001). This might be explained by the finding of
another cleavage site of APP, termed ε-cleavage. It takes place not in
the middle of the transmembrane domain of APP, but close to the
cytoplasmic face of the plasmamembrane. Interestingly, ε-cleavage
shares similarities to several other cellular proteolytic processes as
for example the Notch-site-3 cleavage (Sastre et al., 2001; Weide-
mann et al., 2002). Presumably, processing of the CTF of APP at
this cleavage site is carried out by the γ-secretase complex. It was
shown that γ-secretase-inhibitors preventing Aβ40 and Aβ42 pro-
duction also abolished AICD generation resulting from ε-cleavage.
In addition to that, production of ε-cleaved AICD depends directly
on the expression of PS1 (Yu et al., 2001). Up to now, the exact
underlying mechanism how γ-secretase manages to cleave one sin-
gle protein at different sites still has to be elucidated. It is discussed
that cleavage occurs at aa 40 or 42 first, followed by aminopepti-
dase action on the 57 or 59 aa long AICD peptides, leading to the
generation of truncated AICD (50-99 aa) (Gu et al., 2001; Chavez-
Gutierrez et al., 2012). Another explanation is given by a model, in
which APP is first cleaved at aa 49 or 50 resulting in the generation
of AICD (50-99 aa) and the corresponding Aβ counterparts Aβ1–
48 and Aβ 1–49 (Qi-Takahara et al., 2005) which could possibly be
further truncated by carboxypeptidase activity (Funamoto et al.,
2004). The stepwise degradation of Aβ then results in different
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FIGURE 1 | Proteolytic processing of the amyloid precursor protein
(APP) and Notch. APP processing: in the amyloidogenic processing
pathway, APP is cleaved by the β-secretase BACE1 generating C99 which
is further cleaved to the Amyloid-β peptide (Aβ). The non-amyloidogenic
processing pathway is initiated by α-secretase cleavage of APP within the
Aβ domain, thus precluding the generation of Aβ. α- and β-secretase
cleavage releases the soluble forms of APP, sAPPα, and sAPPβ,
respectively, into the extracellular space. The remaining membrane-bound
C-terminal fragments C83 and C99 are further processed by the
γ-secretase complex leading to the generation of the non-toxic p3 from
C83 or of the amyloidogenic Aβ peptide from C99. Aβ is rapidly degraded
by several enzymes, for example neprilysin (NEP), insulin-degrading
enzyme (IDE), endothelin-converting enzyme (ECE), and angiotensin
converting enzyme (ACE). In both processing pathways the APP
intracellular domain (AICD) is released into the cytosol. Notch processing:
after maturation S1 cleavage of the Notch receptor precursor by a furin-like
convertase, Notch is processed similarly to APP. Ligand binding triggers
the S2 cleavage by the α-secretase TACE/ADAM17 leading to the release
of the Notch extracellular domain into the extracellular space. The
remaining membrane-bound fragment Notch extracellular truncation
(NEXT) is further processed by the γ-secretase complex resulting in the
release of the Notch intracellular domain (NICD) from the membrane.
Aβ species (38–43 aa in length) (Chavez-Gutierrez et al., 2012).
Alternatively, it is discussed that γ-secretase possibly cleaves APP
simultaneously at several sites or that other proteases are involved
in this process.Yu et al. (2001) proposed the model of a membrane-
resident, multicatalytic protease introducing non-selectively the
cleavage of membrane proteins by resident enzymes. Caspase-3 is
also reported to truncate AICD and hence to produce the 31 aa
peptide C31 (Gervais et al., 1999), which was shown to be elevated
in AD brains and to be involved in cell death pathways (Lu et al.,
2000).
The homologs APLP1 and APLP2, lacking the Aβ region, are
processed similarly to APP by α-, β-, and γ-secretase cleavage gen-
erating the APLP intracellular domains ALID1 and ALID2 (Walsh
et al., 2003; Eggert et al., 2004).
THE Aβ DEGRADING ZINC-METALLOPROTEASE NEPRILYSIN
MECHANISMS OF Aβ CLEARANCE IN BRAIN
As already mentioned, the Aβ levels in brain depend not only
on Aβ production, but also on its removal via different clearance
pathways and enzymatic degradation. Under physiological condi-
tions the peptide is rapidly cleared from brain by a combination
of several mechanisms, resulting in a half-life of approximately
1–2, 5 h (Savage et al., 1998; Cirrito et al., 2003). Aβ can be
exported from brain across the blood-brain-barrier by the lipopro-
tein receptor-related protein (LRP) and by the P-glycoprotein
efflux pump (pgP/MDR1/ABCB1) (Kang et al., 2000; Shibata et al.,
2000; Lam et al., 2001), whereas the reentry of circulating Aβ from
blood to brain is mainly mediated by RAGE (receptor for advanced
glycation end products) (Deane et al., 2003). In plasma the peptide
is bound by a soluble form of LRP (sLRP) and transported to liver
and kidneys, which mediate the systemic clearance of unbound
Aβ and of sLRP-Aβ complexes (Sagare et al., 2007, 2012). Further-
more, phagocytosis by microglia followed by lysosomal degrada-
tion and perivascular drainage along basement membranes into
the CSF contributes to Aβ removal from brain (Rogers and Lue,
2001; Preston et al., 2003). A diversity of enzymes is capable of
cleaving Aβ at a single or at multiple sites, most of them are metal-
loproteases differing in their regional and subcellular distribution,
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their pH-optima and their ability to degrade the different species
of the peptide (Miners et al., 2011; Saido and Leissring, 2012).
Some Aβ degrading enzymes are localized within the secretory
pathway and catabolize intracellular Aβ prior to its secretion into
the extracellular space (Eckman et al., 2001; White et al., 2006).
Aβ40 is discussed to be mainly degraded intracellularly, whereas
Aβ42 is basically degraded outside the cell (Hama et al., 2004).
Therefore one might speculate that the different intra- and extra-
cellular pools of Aβ are not removed by one single protease, but
rather by several enzymes working cooperatively together (Saido
and Leissring, 2012). Aβ exists in a dynamic equilibrium of soluble
monomeric, oligomeric, and fibrillar forms (Dahlgren et al., 2002).
Fibrillization is dependent on the formation of β-sheet-structures
between the residues 18 and 42 making this region less accessible
to proteolytic cleavage (Crouch et al., 2009). Therefore, all known
Aβ degrading enzymes are capable of cleaving monomeric Aβ, but
most of them show a restricted ability to degrade oligomeric or
fibrillar species of the peptide. The proteolysis of Aβ is generally
assumed to be beneficial, but for most of the resulting products
their neurotoxic potential or potential physiological relevance still
has to be investigated.
Summary
Aβ levels in brain are influenced not only by Aβ production,
but also by different clearance mechanisms including its clear-
ance to blood and CSF, phagocytosis by microglia, and enzymatic
degradation. The zinc-metalloprotease neprilysin (NEP) is one of
the most prominent Aβ degrading enzymes.
GENERAL FEATURES OF NEP
It has been shown that a neutral endopeptidase sensitive for thior-
phan and phosphoramidon plays a key role in Aβ42 catabolism
in rat brain, leading to the proposal that NEP is the major Aβ
degrading peptidase in vivo (Iwata et al., 2000). In line with these
results NEP deficiency results in twofold elevated levels of endoge-
nous Aβ40 and Aβ42 in different brain regions and in defects in
the degradation of exogenously administered Aβ42 (Iwata et al.,
2001). Today NEP is one of the major and best characterized Aβ
degrading enzymes (Hersh and Rodgers, 2008).
Neprilysin is also named CALLA (common acute lymphocytic
leukemia (ALL) antigen), enkephalinase, neutral endopeptidase
24.11, and CD10 antigen (Brown et al., 1974; Schwartz et al.,
1980; Letarte et al., 1988). It belongs to the family of M13 zinc-
metalloendopeptidases and is an ubiquitously occurring type II
integral membrane protein consisting of 742 aa with a molecular
weight ranging from 85 to 110 kDa depending on differences in its
glycosylation (Relton et al., 1983; Malfroy et al., 1988). It is highly
expressed in kidney, but also in other tissues like brain (Erdos and
Skidgel, 1988). The active center of the enzyme faces the extracel-
lular side of the membrane, an ideal topology for the degradation
of peptides located in the extracellular space or associated to the
membrane (Fukami et al., 2002).
The human NEP gene [MME, epicatechin (EC) 3.4.24.11] maps
to chromosomal region 3q25.1–q25.2 and is composed of 24
exons, highly conserved among mammals (D’Adamio et al., 1989).
The expression of the NEP gene is controlled by at least two dif-
ferent promoters and varies between different tissues. Alternative
splicing in the 5′-untranslated region results in four separate
mRNA transcripts without affecting the coding region (Li et al.,
1995). The protein consists of a short N-terminal cytosolic region,
a single transmembrane helix and a large extracellular domain
containing the typical HEXXH zinc binding motif that is essen-
tial for the proteolysis of its various substrates described below
(Barnes et al., 1995; Turner et al., 2001), preferentially oligopep-
tides consisting of up to 40 aa (Oefner et al., 2000). NEP is involved
in neuropeptide signaling and in the regulation of vascular tone
(Roques et al., 1993). Moreover, it is used as an important cell-
surface marker in the diagnosis of human acute lymphocytic
leukemia (ALL) (Brown et al., 1975) and reported to play a role
in the progression of several other cancers (Gohring et al., 1998;
Papandreou et al., 1998). In the central nervous system NEP is
mainly expressed by neurons (Matsas et al., 1986), but also by acti-
vated astrocytes and microglia (Fisk et al., 2007; Hickman et al.,
2008). In neurons NEP is subcellularly localized along axons and
synapses (Fukami et al., 2002) where NEP mediated Aβ degrada-
tion mainly takes place (Barnes et al., 1992; Hama et al., 2001;
Iwata et al., 2004). This subcellular localization underlines the role
of NEP in the degradation of several neuropeptides, for example
enkephalins, substance P, neuropeptide Y, tachykinins, bradykinin,
and somatostatin (Matsas et al., 1984; Roques et al., 1993; Barnes
et al., 1995). The in vivo functions of NEP have been analyzed by
utilizing NEP gene disrupted mice. These animals show enhanced
lethality to endotoxin treatment, probably due to the role of NEP
in the metabolism of pro-inflammatory peptides, lower blood
pressure, and higher microvascular permeability (Lu et al., 1995).
Summary
Neprilysin is an 85–110 kDa zinc-dependent membrane metal-
loprotease degrading numerous extracellular located substrates,
among them Aβ and several neuropeptides. The enzyme is
expressed in various tissues including the central nervous system,
where it is mainly present in neurons with a subcellular localization
along axons and synapses.
NEP AND ITS FUNCTION IN Aβ DEGRADATION
The ability of NEP to cleave Aβmonomers in vitro as well as in cell
culture was analyzed in different studies (Howell et al., 1995; Hama
et al., 2001; Kanemitsu et al., 2003; Marr et al., 2003). It is worth
mentioning that NEP is reported to cleave monomeric Aβ40 more
efficiently than Aβ42. In an in vitro degradation assay only 27% of
the added monomeric Aβ42 was degraded by NEP, in contrast the
enzyme cleaved 73% of the added Aβ40 monomers (Kanemitsu
et al., 2003). In the meantime several cleavage sites of NEP within
the Aβ sequence have been identified (Carson and Turner, 2002;
Wang et al., 2006; Miners et al., 2011), which are summarized in
Figure 2. The ability of the enzyme to degrade Aβ oligomers and
fibrils is controversially discussed, e.g., NEP seems to be capa-
ble of degrading synthetic oligomers formed non-enzymatically
from synthetic Aβ40 and Aβ42 (Kanemitsu et al., 2003), but not
oligomers naturally secreted from cells (Leissring et al., 2003).
Interestingly, some of the pathogenic APP mutations result in
a higher resistance of Aβ to NEP-catalyzed proteolysis. Tsubuki
et al. incubated wildtype Aβ40 and Aβ40 peptides containing the
Dutch, Flemish, Italian, and Arctic mutation (Van Broeckhoven
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FIGURE 2 | Cleavage sites of NEP within the Aβ-sequence and
positions of FAD mutations. Within the Aβ sequence there are several
cleavage sites for neprilysin (NEP), the cleavage positions of α-, β-, and
γ-secretase are also indicated. Some of the pathological point mutations
within the Aβ sequence are reported to result in a higher resistance of the
peptide to NEP-catalyzed proteolysis (highlighted in red), other known
mutation sites are shown in orange. The amino acid numbers are referring
to the APP695 isoform.
et al., 1990; Hendriks et al., 1992; Nilsberth et al., 2001; Bugiani
et al., 2010) (indicated in Figure 2) with purified mouse NEP prior
to analysis of the peptides by high-performance liquid chromatog-
raphy (HPLC). All mutated Aβ peptides were more resistant to
NEP-catalyzed cleavage in comparison to wildtype Aβ40 (Tsubuki
et al., 2003). Betts et al. analyzed the same peptides and found
significant differences in their tendency to aggregate. Further-
more, they demonstrated aggregated wildtype Aβ40 to be less well
degraded than its monomeric form. Proteolysis analysis of the
mutated monomeric peptides by HPLC revealed that all mutated
Aβ species with exception of the Flemish mutated peptide are
degraded equally well by NEP as wildtype Aβ. Only Aβ bearing
the Flemish mutation was degraded significantly more slowly by
NEP. The authors concluded, that the most likely explanation for
this divergence in results lies in differences in the aggregation state
of the analyzed peptides (Betts et al., 2008).
The in vivo function of NEP in Aβ degradation reported by
Iwata et al. has been verified in several other studies. It was
demonstrated that intraneuronal Aβ42 deposits and Aβ42 induced
neuronal loss can be sufficiently suppressed in transgenic D.
melanogaster expressing human NEP and Aβ42 (Iijima-Ando et al.,
2008). Moreover, KO of NEP in mice result in an increase in the
levels of soluble and oligomeric Aβ leading to impaired synap-
tic plasticity and cognitive abnormalities in APP transgenic and
wildtype animals (Huang et al., 2006; Madani et al., 2006). Con-
versely,overexpression of NEP in AD mouse models by using either
genetic or viral approaches leads to decreased cerebral Aβ lev-
els, inhibition of plaque formation, and enhanced life expectancy
(Leissring et al., 2003; Marr et al., 2003; Iwata et al., 2004; Poirier
et al., 2006). In line with this, improved behavioral performance
and cognitive functions in the NEP overexpressing animals is
reported (Poirier et al., 2006; El-Amouri et al., 2008; Spencer
et al., 2008). Recently, Iwata et al. (2013) demonstrated the AAV
vector-mediated NEP gene transfer into an AD mouse model to
significantly reduce monomeric, dimeric, trimeric, and tetrameric
forms of Aβ accompanied by alleviation of abnormal learning and
memory function. Further, the administration of recombinant sol-
uble NEP by intracerebral injection into AD mice was reported to
result in significantly reduced accumulation of Aβ and additionally
in improved behavioral performance on the water maze test (Park
et al., 2013). Conversely, Meilandt et al. (2009) failed to assess
behavioral improvement in the Morris water maze test and reduc-
tion of Aβ oligomers in hAPP/NEP double transgenic animals
despite 50% reduction in soluble Aβ levels and prevention of
plaque formation, demonstrating the inability of NEP to cleave
some naturally occurring oligomeric Aβ species.
Furthermore, NEP is discussed to be a genetic risk factor for
the development of AD. It has been demonstrated that individuals
with certain polymorphisms in the NEP gene have an increased
risk for AD (Helisalmi et al., 2004) and the susceptibility to AD
is even higher when insulin-degrading enzyme (IDE), another
Aβ-degrading enzyme, also shows a polymorphism (Vepsalainen
et al., 2009). In contrast, other studies reported a lack of associa-
tion between NEP polymorphisms and the risk for developing AD
(Sodeyama et al., 2001; Oda et al., 2002; Wood et al., 2007).
Summary
While NEP is capable to cleave Aβ monomers in vitro and in vivo,
its ability to degrade oligomeric Aβ species is controversially dis-
cussed. Decreased NEP levels were shown to result in increased Aβ
levels, impaired synaptic plasticity, and cognitive abnormalities in
WT and APP transgenic mice. Conversely, enhanced NEP levels in
AD mouse models lead to reduced Aβ levels accompanied by an
improvement in some behavioral tests.
ALTERED NEP REGULATION IN AGING AND AD
As already mentioned, defective Aβ clearance has been long
hypothesized to predominate in LOAD. Therefore, a possible cor-
relation of NEP levels with the progression of AD and with normal
aging has been intensively investigated.
REDUCTION OF NEP LEVELS IN AD
In general, NEP seems to be reduced in brain areas early affected
in AD and characterized by extensive plaque load. NEP levels are
decreased in hippocampus (Yasojima et al., 2001a; Carpentier et al.,
2002; Miners et al., 2006), temporal gyrus (Yasojima et al., 2001b),
and cortex (Akiyama et al., 2001; Russo et al., 2005; Wang et al.,
2005b; Miners et al., 2006) in human post mortem AD brains.
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NEP is also reduced in brain vasculature of AD patients (Carpen-
tier et al., 2002; Miners et al., 2006) implicating a role of NEP in
cerebral amyloid angiopathy (CAA). Moreover, alterations in NEP
expression in AD are not restricted to brain tissue since the enzyme
level was found to be also affected in CSF. In patients with mild cog-
nitive impairment (MCI), substantial reduction of CSF NEP activ-
ity was observed followed by an elevation along with the progres-
sion of AD, suggesting that presynaptically located NEP is released
into CSF as a consequence of synaptic disruption (Maruyama
et al., 2005). An inverse relationship between NEP levels and
Aβ accumulation has been shown in temporal and frontal cortex
(Hellstrom-Lindahl et al., 2008) and in the vasculature (Carpentier
et al., 2002) of human AD patients as well as in the hippocampus
of APP transgenic mice (Fukami et al., 2002), indicating that even
a slight reduction in NEP levels for several decades can lead to
increased Aβ levels. However, other studies reported NEP levels
in cortex not to be significantly altered (Hellstrom-Lindahl et al.,
2008), or even elevated (Miners et al., 2009) in human post mortem
AD brains compared to control brains. In the latter study NEP pro-
tein levels and activity, which was measured by the use of a highly
specific immunocapture-based fluorometric activity assay (Miners
et al., 2008), were reported to positively correlate with Braak stage.
Interestingly, in this study NEP level was normalized to a protein
marker for neuronal integrity, the neuron specific enolase (NSE).
Moreover, quite recently Zhou et al. (2013) reported a decrease of
NEP levels in cytoplasm and in contrast an increase in membrane
fractions of MCI and AD brains indicating an altered subcellular
localization of NEP in AD, which might also explain differences
found in literature. Keeping in mind that NEP is a plasma mem-
brane ectoenzyme, the detection of apparently cytoplasmatic NEP
in this study is questionable and might possibly be an artifact
resulting from the extraction process. In astrocytes the expression
of NEP is upregulated in AD, especially in plaque-surrounding
reactive astrocytes as demonstrated for aged APPswe mice (Apelt
et al., 2003) and for human AD brains (Carpentier et al., 2002),
further suggesting a possible role of astrogliosis in Aβ degradation.
Possible explanations for this divergence in results are for exam-
ple methodological differences, differences in the analyzed brain
areas, cell types and in sample preparation. Moreover, there are
severe difficulties in specifically measuring NEP activity which
could lead to different results. Taking in consideration that possibly
a late upregulation of NEP in association with disease progression
exists, difference in disease state of the analyzed individuals is a
critical point for comparing the results of several studies. Addition-
ally, indication exists that normal aging processes can also result in
a reduction of NEP further underlying the importance of compar-
ing stringently age matched controls to post mortem AD brains.
Summary
Neprilysin seems to be reduced in brain areas early affected in AD
and characterized by high plaque load. A decline of NEP levels
in AD has been observed in most of the studies although some
authors assessed converse results.
REDUCTION OF NEP LEVELS DURING AGING
Several studies reported significant reductions of brain NEP lev-
els in aged animals and human beings. NEP mRNA levels decline
during aging in D. melanogaster brains (Iijima-Ando et al., 2008),
similar effects were observed in mammals. NEP levels or enzyme
activity diminish as a function of age in mouse cerebral cortex
(Apelt et al., 2003), hippocampus (Caccamo et al., 2005), in whole
mouse brain homogenate (Carter et al., 2006), and in the hip-
pocampus of aged rats (Briones and Darwish, 2012). Iwata et al.
(2002) further demonstrated by immunohistochemical analysis
of the hippocampus of APP transgenic mice that NEP levels are
selectively decreased in nerve terminals and axons upon aging. In
line with these observations, a negative correlation between brain
NEP levels and age was reported for both non-demented persons
and AD patients (Russo et al., 2005; Hellstrom-Lindahl et al., 2008;
Miners et al., 2009).
Summary
Neprilysin levels seem to be reduced during aging as demonstrated
in aged D. melanogaster, mice, rats, and human beings.
MECHANISMS OF NEP REGULATION
Taking into consideration that NEP expression and activity seem
to be reduced in AD, it can be speculated that increased upregula-
tion of NEP might have beneficial effects. The pathways involved
in the regulation of NEP expression and activity possess an attrac-
tive therapeutic potential and have been further elucidated. Saito
et al. reported that the neuropeptide somatostatin, which is a NEP
substrate (Barnes et al., 1995), is able to upregulate NEP activ-
ity indicating a regulatory feedback cycle. Treatment of primary
neurons with somatostatin results in a higher, somatostatin defi-
ciency in mice in a reduced NEP activity, respectively (Saito et al.,
2005). Pharmacological activation of the somatostatin receptor
subtype-4 increases NEP activity in cortical tissue, suggesting that
the somatostatin receptors are interesting pharmacological tar-
gets for the regulation of enzyme activity (Sandoval et al., 2012).
In addition, NEP expression can be upregulated by the hormone
estrogen in an estrogen receptor α and β dependent manner in
human SH-SY5Y cells (Liang et al., 2010). A decrease of NEP
activity combined with elevated brain Aβ levels were observed
in ovariectomized animals with estrogen treatment reversing the
effects (Petanceska et al., 2000; Huang et al., 2004). We and oth-
ers have shown the secosteroid vitamin D to be involved in the
regulation of NEP in vitro and in vivo. Vitamin D deficiency in
mice results in a lowered NEP expression and enzyme activity,
while vitamin D supplementation elevates NEP levels in cultured
cells and in the brain of aged rats (Briones and Darwish, 2012;
Grimm et al., 2013). The reported downregulation of somato-
statin (Davies et al., 1980; Lu et al., 2004; Gahete et al., 2010),
estrogen (Manly et al., 2000; Barron and Pike, 2012), and vitamin
D (Annweiler et al., 2011; Llewellyn et al., 2011) in aged individu-
als and AD patients may explain the downregulation of NEP upon
aging and in AD. Furthermore, oxidative stress, which is increased
in AD brain, leads to decreased half-life of NEP and decreased
enzyme activity (Wang et al., 2003; Shinall et al., 2005). Oxida-
tive stress initiates the formation of 4-hydroxy-non-enal (HNE),
a by-product of lipid peroxidation reported to be increased in
AD brains, interacting with, and inactivating a variety of enzymes
including NEP (Lauderback et al., 2001; Wang et al., 2003). In
cell culture studies using SK-N-SH cells, green tea extract (Melzig
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and Janka, 2003), and more specifically the antioxidative green
tea polyphenols EC, epigallocatechin (EGC), and epigallocatechin
gallate (EGCG) among other components increase cellular NEP
activity (Ayoub and Melzig, 2006). In 2011 the small neuroprotec-
tive peptide humanin, whose cDNA was found in an AD patients
brain (Hashimoto et al., 2001), was shown to increase NEP expres-
sion in the hippocampus of an AD mouse model (Niikura et al.,
2011). Kynurenic acid (KYNA), one of the main products of the
kynurenine pathway, is another neuroprotective component that is
able to increase NEP expression, protein levels and activity in cul-
tures of human neuroblastoma SH-SY5Y cells and mouse cortical
neurons (Klein et al., 2013).
Summary
Several naturally occurring compounds, e.g., somastatin, estrogen,
vitamin D, and components of green tea are able to upregulate NEP
expression and/or activity. In contrast, oxidative stress was shown
to lower the half-life and activity of the enzyme.
Most discussed in the last years is the regulation of NEP
expression by AICD in a Notch-like signaling pathway.
AICD NUCLEAR SIGNALING AND ITS IMPACT ON THE
REGULATION OF NEP
STRIKING SIMILARITIES BETWEEN NOTCH AND APP PROCESSING
Like APP, the Notch receptors are single-pass type I transmem-
brane proteins that are processed with some striking similarities
to APP (shown in Figure 1). In response to an extracellular
signal, Notch is sequentially cleaved within its extracellular domain
followed by intramembrane cleavage and the release of an extra-
and intracellular fragment.
During maturation S1 cleavage of the Notch receptor precursor
by a furin-like convertase takes place in the Golgi network and the
fragments are shuttled to the cell surface as a non-covalently linked
heterodimeric receptor molecule (Kopan and Turner, 1996; Logeat
et al., 1998). The extracellular domain of Notch contains epider-
mal growth factor (EGF)-like repeats which mediate the binding
of DSL ligands (Delta, Serrate/Jagged). This initiates S2 cleavage of
Notch catalyzed by a member of the ADAM/tumor necrosis factor-
α-converting enzyme (TACE) metalloprotease family releasing the
Notch extracellular domain and the transient intermediate peptide
Notch extracellular truncation (NEXT) (Mumm et al., 2000). In
contrast to Notch processing there is no equivalent APP matura-
tion and ligand binding necessary for APP to be further processed.
Like the APP CTFs, NEXT is a substrate for the multimeric γ-
secretase enzyme complex cleaving NEXT in its intramembrane
region (De Strooper et al., 1999; Sastre et al., 2001). Theγ-secretase
mediated S3 cleavage of NEXT, which shares similarities with
the γ-/ε-cleavage of APP CTFs regarding the membrane topol-
ogy, presenilin-dependence, cleavage before a valine residue, and
inhibition profile (Weidemann et al., 2002), releases the mobile
cytoplasmic subunit Notch intracellular domain (NICD) from the
membrane (Schroeter et al., 1998). NICD migrates to the nucleus
and heterodimerizes with CSL (CBF1-SU(H)-LAG1) (Schroeter
et al., 1998), which represses Notch target genes through recruit-
ment of corepressor complexes in the absence of AICD. NICD
displaces these corepressors, recruits a coactivator complex, and
hence activates transcription. A role of NICD in the transcriptional
regulation of several genes is well established (Borggrefe and
Oswald, 2009). Due to the obvious similarities between APP and
Notch in their protein structure and proteolytic cleavage, it is rea-
sonable to assume that APP takes part in the regulation of other
genes via its intracellular domain as well. Such a function of AICD
is controversially discussed.
Summary
The high similarities between APP and Notch receptor processing
by ADAM and γ-secretase activity leading to the generation of a
large ectodomain and a short intracellular fragment indicate that
AICD is likely to regulate the expression of multiple genes similar
to NICD.
THE MECHANISMS OF AICD NUCLEAR SIGNALING
Within AICD there are several sequence motifs of functional
relevance which are summarized in Figure 3, e.g., the 653YTSI
sequence, the 667VTPEER sequence, and the 681GYENPTY motif
with the aa numbers referring to the APP695 isoform. Tyr653
in the YTSI sequence is required for basolateral sorting of APP
in polarized MDCK cells (Lai et al., 1998). The VTPEER site
appears to be involved in pathophysiology and Thr668 is the
major phosphorylation site of APP (Suzuki and Nakaya, 2008).
Far more attention has been addressed to the GYENPTY sequence
which includes a NPXY motif serving as internalization signal
for membrane proteins (Chen et al., 1990) and interacting with
adapter proteins containing a phosphotyrosine-binding (PTB)
domain (Uhlik et al., 2005). Interestingly, the residue Tyr682 is
essential for the function of APP in developmental processes.
Barbagallo et al. (2011) showed expression of APP with the Y682G
mutation in APLP2-KO mice not to be able to compensate the
early postnatal lethality and neuromuscular synapse defects of
APP/APLP2-KO mice.
After first description of AICD (then termed AID) by Passer
et al. (2000), early experiments regarding a potential function
of AICD in gene transcription were carried out by Cao and
Sudhof in 2001 by using fusion proteins of APP and the DNA
binding domains of the transcription factors Gal4 and LexA in
combination with Gal4 and LexA dependent reporter plasmids
to measure transactivation of transcription. Coexpression of the
fusion proteins with the reporter plasmids resulted in only minor
transactivation of transcription in HEK293, COS7, and HeLa cells,
indicating that APP may need binding of a cofactor. Fe65 was
identified as the major protein interacting with the APP cyto-
plasmic tail by yeast two-hybrid screens. Indeed, cotransfection
of Fe65 and the APP-Gal4 or APP-LexA fusion proteins greatly
stimulated transcription showing Fe65 to be the cofactor required
for the function of AICD in gene regulation. Further yeast two-
hybrid assays revealed an interaction of Tip60 with the PTB1 site
of Fe65. GST-Tip60 efficiently pulled down APP together with
Fe65 indicating the existence of a stable trimeric complex com-
posed of the APP cytoplasmic tail, Fe65 and Tip60 that is able
to transactivate transcription in vitro (Cao and Sudhof, 2001).
The members of the Fe65 protein family, Fe65 and the Fe65 like
proteins 1 and 2 (Fe65L1 and Fe65L2) are multidomain adaptor
proteins that form multiprotein complexes. They all have a WW
domain and two PTB domains and bind to AICD via their PTB2
Frontiers in Aging Neuroscience www.frontiersin.org December 2013 | Volume 5 | Article 98 | 7
Grimm et al. Neprilysin and Aβ clearance
FIGURE 3 | Sequence of the APP intracellular domain (AICD)
including important sequence motifs and adapter protein binding
sites. The YTSI sequence is required for basolateral sorting of APP, the
VTPEER site is involved in pathophysiology and includes the Thr668
residue, which is the major phosphorylation site of APP. The GYENPTY
sequence is reported to be important for the interaction of AICD with
adaptor proteins containing a phosphotyrosine-binding (PTB) domain.
Caspase-3 cleavage of AICD takes place between D664 and A665 and
results in the formation of C31 peptide. The amino acid numbers are
referring to the APP695 isoform.
domain (McLoughlin and Miller, 2008). Fe65 increases the stabil-
ity of AICD (Kimberly et al., 2001; Kinoshita et al., 2002), which
has a reported half-life of not more than 5 min (Cupers et al., 2001)
due to its rapid degradation in the cytosol by IDE (Edbauer et al.,
2002; Farris et al., 2003), the proteasome (Nunan et al., 2003),
and the endosomal/lysosomal protease Cathepsin B (Vingtdeux
et al., 2007; Asai et al., 2011) enabling AICD to translocate to the
nucleus (see Figure 4). Further, the importance of Fe65 in APP
function in vivo is indicated by the phenotype of Fe65/Fe65L1 gene
deleted mice, showing cortical dysplasia like APP/APLP1/APLP2
triple KO animals (Guenette et al., 2006). Tip60 is a histone acetyl-
transferase (Yamamoto and Horikoshi, 1997) acting in chromatin
remodeling, DNA repair, transcription, and apoptosis (Ikura et al.,
2000). The existence of the trimeric protein complex consisting of
fluorescent protein-tagged AICD, Fe65, and Tip60 (termed AFT-
complex) was further confirmed by colocalization of the three
proteins in spherical nuclear spots (Von Rotz et al., 2004; Goodger
et al., 2009). Moreover, Konietzko et al. (2010) demonstrated by
confocal analysis that nuclear export blockade allows to reveal the
nuclear localization of endogenous AICD at the level of nuclear
transcription territories.
All these observations resulted in the model that Fe65 binds
AICD after its release from the membrane by γ-secretase cleav-
age, followed by the translocation of the Fe65/AICD complex to
the nucleus, where it associates with Tip60 leading to the forma-
tion of AFT complexes. Although this model is suggested by most
authors, there are some studies suggesting alternative mechanisms
for signal transduction by APP (Muller et al., 2008). These models
suggest an independent translocation of AICD and Fe65 to the
nucleus (Nakaya and Suzuki, 2006), a conformational change of
Fe65 induced by AICD enabling it to translocate to the nucleus
where it binds Tip60 to form a transcriptionally active AFT com-
plex (Cao and Sudhof, 2004), or the recruitment of Tip60 through
Fe65 by the APP C-terminus independently fromγ-secretase cleav-
age that results in the phosphorylation, stabilization and activation
of Tip60 by cyclin-dependent kinase (CDK) leading to the translo-
cation of the Tip60/Fe65 complex into the nucleus (Hass and
Yankner, 2005). Arguing against some of these alternative mod-
els, the translocation of AICD to the nuclear compartment was
reported by several studies. AICD was found to be located in the
nuclei of cultured cells and even in cortices of APP transgenic mice
(Chang et al., 2006).
Alternatively to Tip60, the transcription factor CP2/LSF/LBP1
can interact with Fe65 and bind to the promoter region of poten-
tial AICD target genes (Zambrano et al., 1998; Kim et al., 2003).
MED12 protein, which is part of the Mediator complex, a large
protein complex transducing signals from specific transcription
factors to RNA polymerase II, binds to Fe65 and Tip60 in the
presence of AICD, providing a direct link of the AICD/Fe65/Tip60
complex to the RNA polymerase II general transcription apparatus
(Xu et al., 2011).
More than 20 other adaptor proteins that bind AICD or the
Fe65-AICD complex have been identified (Borquez and Gonzalez-
Billault, 2012) (see Figure 3), the most prominent examples are
reviewed here. Nuclear signaling of APP is prevented by MINT-
1/X11α by retaining AICD in the cytosol instead of translocating
it to the nucleus (Von Rotz et al., 2004). The protein Dexras1 was
shown to bind to the PTB2 domain of Fe65 and to compete with
APP for binding to Fe65 leading to a suppression of FE65-APP
mediated transcription (Lau et al., 2008). Interaction of AICD
with the ubiquitin-like Nedd8 results in the dissociation of AICD
from Fe65 combined with the reduction of AFT complexes and
of AICD transcriptional activity (Lee et al., 2008). In contrast, the
Janus kinase interacting protein-1 (JIP-1) in combination with
AICD can activate gene expression in a Fe65 independent manner
(Scheinfeld et al., 2003), with transport of AICD to nuclei and
the subsequent docking to Tip60 resulting in the formation of
AICD-JIP-1-Tip60 (AJT) complexes showing a different, speckle
like morphology compared to AFT complexes (Von Rotz et al.,
2004). Dimeric 14-3-3γ binds to the VTPEER sequence of AICD
and to a sequence between the WW domain and the first PTB
domain of Fe65 and facilitates gene transactivation by enhancing
the AICD-Fe65-association (Sumioka et al., 2005). The phospho-
rylation status of AICD affects the affinity of binding partners
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FIGURE 4 | Model of potential mechanism of AICD-mediated gene
regulation. The two different APP cleavage pathways have been shown to
occur in distinct subcellular localizations. While the non-amyloidogenic
pathway by α- and γ-secretase cleavage takes place at the plasma
membrane, the amyloidogenic APP processing is discussed to take mainly
place in endosomes. The APP intracellular domain (AICD) generated by
non-amyloidogenic APP processing is rapidly degraded by, e.g., the
proteasome, insulin-degrading enzyme (IDE), Cathepsin B, and Caspase-3
into smaller fragments. In contrast, AICD generated by amyloidogenic APP
processing can be stabilized by binding to Fe65 or JIP-1 and translocated
to the nucleus, where the gene regulatory AFT (AICD, Fe65, Tip60) or AJT
(AICD, JIP-1, Tip60) complexes are formed. Alternatively to Tip60, the
transcription factor CP2/LSF/LBP1 is hypothesized to interact with Fe65
and activate AICD-mediated gene transcription. Binding to the MED12
protein links these complexes to the RNA polymerase transcription
apparatus. Additionally binding of AICD to MINT1/X11α or the interaction of
Dexras1 with the PTB2 domain of Fe65 results in an inhibition of
Fe65/AICD induced transcription.
and therefore influences the Fe65/AICD-mediated transcriptional
control (Ando et al., 2001).
Experimental evidence suggests that not all pools of AICD are
active in nuclear signaling. As Aβ, sAPPβ and AICD are mainly
formed from APP695, this isoform mainly expressed in neurons
seems to have a higher affinity or turnover by β-secretase com-
pared to the other isoforms. In line, APP751 and APP770 were
shown to be mainly processed by α- and γ-secretase cleavage
(Kametani et al., 1993; Belyaev et al., 2010). Only the overex-
pression of APP695 results in an increase of AICD levels in
nuclear fractions of SH-SY5Y cells (Belyaev et al., 2010). This
may indicate a neuronal specificity of the AICD-mediated gene
regulatory mechanism with APP695 being the major APP iso-
form in neuronal, but not in non-neuronal cells (Sandbrink et al.,
1994). Although AICD derives from both amyloidogenic and
non-amyloidogenic APP processing pathways and an α-secretase-
dependent AICD generation was reported (Kume et al., 2004),
several studies demonstrated the β-secretase mediated APP cleav-
age in endosomal compartments to be mainly responsible for the
generation of transcriptionally active AICD species. Interestingly,
Passer et al. (2000) already reported in the first study describ-
ing the existence of AICD, that overexpression of C99 results in
larger amounts of AICD than overexpression of C83. Blocking
the amyloidogenic APP processing by inhibition of endocytosis or
inhibition/genetic deletion of BACE1 in fibroblasts, HEK293 cells,
and primary neurons leads to a reduced translocation of AICD
to nuclear AFT complexes, while inhibition of α-secretase has no
effect on AFT-complex generation (Goodger et al., 2009). This was
Frontiers in Aging Neuroscience www.frontiersin.org December 2013 | Volume 5 | Article 98 | 9
Grimm et al. Neprilysin and Aβ clearance
confirmed by Belyaev et al. (2010) showing that inhibition of β-
and γ-, but not α-secretase in SH-SY5Y cells leads to abolished
AICD-mediated upregulation of the AICD target gene NEP. The
results of the studies mentioned above resulted in the model (illus-
trated in Figure 4), that AICD released by α/γ-secretase cleavage
at the plasma membrane is rapidly degraded in the cytosol by
IDE and other proteases like Cathepsin B and truncated into C31
by caspase-3 activity. In contrast, the AICD generated by amy-
loidogenic APP processing requiring the endocytotic pathway, can
translocate to the nucleus due to a shorter distance resulting in less
degradation of the peptide. There it forms a complex with MED12,
Fe65, and Tip60 that is able to regulate gene expression (Beckett
et al., 2012). Conversely, in a study by Flammang et al. AICD was
shown to be predominantly derived from C99. In this study C84
or C100 was overexpressed in E. coli, purified and supplemented
with mammalian γ-secretase containing membranes. Analyzing
the generated amount of AICD revealed that under these condi-
tions γ-secretase has a higher turnover of C99 compared to C83
resulting in a higher level of C99 derived AICD. Similar results were
obtained by utilizing cell-derived, membrane-embedded C83/C99
from C83/C99 overexpressing mammalian cells (Flammang et al.,
2012). This is consistent with the data generated by Passer et al.,
Goodger et al., and Belyaev et al., but argues against the cyto-
plasmatic AICD degradation to be responsible for the inefficiency
of C83 derived AICD in forming AFT complexes and regulating
transcription. The existence of a substrate inhibitory domain in
C83 (ASID, Aβ17–23) that inhibits γ-secretase activity is a possi-
ble explanation for the reduced affinity of γ-secretase toward C83
(Tian et al., 2010).
Summary
Amyloid precursor protein intracellular domain binds to Fe65
after its release from the membrane. This is followed by the
translocation of the AICD/Fe65 complex to the nucleus, where
the association with the histone acetyltransferase Tip60 and the
formation of the transcriptionally active AFT complex takes place.
Experimental evidence suggests that the AICD active in nuclear
signaling is produced mainly from the APP695 isoform in a
β-/γ-secretase-dependent manner.
IMPACT OF AICD IN THE REGULATION OF NEP
Remarkably, in the case of an AICD-mediated upregulation of
NEP, one APP cleavage product, AICD indirectly regulates the life-
time of another APP cleavage product, Aβ, by upregulation of its
degradation resulting in a regulatory cycle, in which γ-secretase is
responsible for Aβ production and modulates its degradation at
the same time. Importantly, it has been shown, that Aβ and AICD
generation by γ-secretase could be independently regulated (Chen
et al., 2006;Wiley et al., 2007; He et al., 2010). In this cycle decreased
AICD formation, for example by reduction of γ-secretase activity,
genetic deletion of APP, or prevention of AICD transport to the
nucleus, should result in reduced NEP expression leading to higher
Aβ levels. This has been analyzed by several groups over the past
years with inconsistent outcomes. An overview of the performed
experiments and the generated results is given in Table 1.
Pardossi-Piquard et al. published, that γ-secretase inhibition
and genetic deletion of PS1/PS2, nicastrin, Fe65, and the APP
family members results in decreased NEP expression and activ-
ity in vitro and in vivo. In this studies NEP expression and
activity were shown to be restored by transient expression of
PS1, PS2, or the intracellular domains of APP, APLP1, and APLP2
(Pardossi-Piquard et al., 2005, 2006, 2007). In line with these find-
ings, pharmacological inhibition of γ-secretase or RNAi-mediated
APP knockdown in NB7 and SK-N-SH cells leads to significantly
decreased NEP mRNA levels as reported by Xu et al. Interest-
ingly, similar effects on NEP and other potential AICD target genes
were observed by RNAi-mediated knockdown of MED12 identi-
fying the protein as a transducer of AICD nuclear signaling for
the first time (Xu et al., 2011). Furthermore, NEP gene promot-
ers are transactivated by AICD in TSM1 neurons and fibroblasts
shown by luciferase reporter assays (Pardossi-Piquard et al., 2005).
A direct physical interaction of AICD with the NEP promoter was
further confirmed by supergel shift assay analysis in HEK293 cells
and chromatin immunoprecipitation (ChIP) (Pardossi-Piquard
et al., 2005; Belyaev et al., 2009). AICD binds directly to the NEP
promoter NB7 cells, which highly express NEP, and rat primary
cortical neurons, but not in HUVEC (primary human umbilical
vein endothelial) and SH-SY5Y cells, which only show a low NEP
expression. In this study excess histone deacetylation was shown
to be involved in NEP repression (Belyaev et al., 2009).
Other groups failed to reproduce the observed effects of AICD
signaling on NEP expression, even by using broadly similar
methodologies and partly the same cells for their experiments.
Hebert et al. (2006) found no consistent effect on NEP expres-
sion in several cell lines treated with γ-secretase-inhibitors and
in fibroblasts bearing genetic deficiencies in the γ-secretase com-
plex or the APP family members. There was also no alteration
of NEP levels in tissues of APP/APLP1, PS1, or Aph1a gene dis-
rupted mouse embryos. Chen et al. also reported the lack of both
PS1 and PS2 expression in mouse embryonic stem cells (BD8)
not to alter NEP levels. In PS double KO fibroblasts NEP levels
are decreased, but rescued γ-secretase activity by introduction of
PS1 failed to rescue the effect on NEP levels. Cellular NEP levels
are unaffected as well by inhibition of γ-secretase in fibroblasts,
BD8, and HEK293 cells and by introduction of AICD, Tip60, and
Fe65 in PS double KO BD8, BD8 wildtype, and HEK293 wildtype
cells. Moreover, there was no change in NEP levels and activity
in APP and APLP2 single KO mouse brain homogenates found
(Chen and Selkoe, 2007). In a further study, gene-chip microar-
ray analysis revealed no alterations of NEP expression in APP KO
and PS1/PS2 double KO fibroblasts along with no alterations of
NEP protein levels in APP/APLP2 single and double KO fibroblasts
(Huysseune et al., 2009).
Several factors influencing the experimental outcomes, for
example cell types, clonal heterogeneity,density and age of the used
cells, transgenic mouse models (single vs. double KO), and differ-
ences in incubation times/concentrations of the used inhibitors
might explain the discussion about a function of AICD in gene
regulation (Pardossi-Piquard et al., 2007; Bauer et al., 2011). Dif-
ferent cell lines may vary in the ratio of constitutive vs. regulated
NEP expression. In consequence, detection of AICD regulated
NEP expression is probably not possible in all cells. In line with this
hypothesis Hong et al. (2012) failed to detect an influence of AICD
on NEP in human prostate cells. As already mentioned, the distinct
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APP isoforms differ markedly in their ability to modulate NEP
expression with transcriptionally active AICD being preferentially
derived by β-secretase cleavage of APP695, the most prominent
APP isoform in neuronal, but not in non-neuronal cells (Belyaev
et al., 2010). This could additionally explain cell type specificity of
the signaling pathway and the failure to observe AICD-mediated
transcriptional activation in studies using non-neuronal cell lines.
Nevertheless, physical and functional interaction of AICD
and regulatory elements of the NEP promoters has been clearly
demonstrated (Pardossi-Piquard et al., 2005; Belyaev et al., 2009).
Binding of AICD to these elements is followed by the displace-
ment of HDAC1 (histone deacetylase 1) and hence the activation
of transcription (Belyaev et al., 2009; Xu et al., 2011). The remod-
eling of chromatin by histone acetylation and deacetylation is an
important mechanism of regulating gene expression in general.
NEP expression in neuronal cells was shown to be repressed via
competitive binding of HDACs to its promoter. Sodium valproate
(valproic acid, VA), an anticonvulsant showing HDAC-inhibitory
properties, is able to restore AICD promotor binding as well as
NEP expression in vitro and in vivo and improves animal behav-
ior and memory (Qing et al., 2008; Belyaev et al., 2009; Zhuravin
et al., 2011; Nalivaeva et al., 2012), indicating the AICD dependent
regulation of NEP to be an interesting therapeutical target.
Imatinib (Gleevec), a tyrosine kinase inhibitor used for the
treatment of several cancers, shows another mode of action in the
upregulation of NEP. Incubation of H4 cells with Imatinib results
in reduced Aβ levels accompanied by increased levels of both AICD
and NEP (Eisele et al., 2007). A causative link between these effects
was later given by the observation that the Imatinib-induced NEP
elevation is totally abolished by genetic deletion of APP/APLP2
in fibroblasts. The authors suggest, that Imatinib treatment slows
down AICD degradation resulting in increased NEP levels, higher
Aβ degradation and hence to a reduction in Aβ levels (Bauer et al.,
2011).
Summary
The impact of AICD on NEP expression has been demonstrated
in several models by the use of different methods. In line a
direct interaction between AICD and the NEP promoter region
has been shown. In contrast, other studies exist reporting no
AICD-mediated NEP regulation. NEP expression is upregulated
by sodium valproate and Imatinib via inhibition of HDACs and
of AICD degradation, respectively.
In conclusion, the regulation of NEP by AICD cannot be
assumed in general, but rather for specific pools of AICD in cer-
tain tissues. It represents a potential therapeutic target for AD.
However, further studies elucidating potential side effects are nec-
essary, especially by keeping in mind the high repertoire of NEP
substrates and the potential role of AICD in the regulation of genes
involved in a variety of cellular functions, as for example the ini-
tiation of apoptosis. A similar situation occurs by the approach
of γ-secretase inhibition to treat AD because of various known
targets of the γ-secretase.
FURTHER POTENTIAL AICD TARGET GENES
The controversial results obtained by AICD-mediated regulation
of NEP is also reflected by other targets assumed to be regulated
by AICD. Here we briefly summarize these studies to further eval-
uate the general transcriptional regulation mediated by AICD and
therefore to get an impression why different results might have
been obtained in literature.
Potential target genes of AICD nuclear signaling include
retinoic acid-responsive genes (Gao and Pimplikar, 2001),
KAI1/CD82 (Baek et al., 2002), glycogen synthase kinase-3β
(GSK3β) (Kim et al., 2003), APP, BACE1, Tip60 (Von Rotz et al.,
2004), NEP (Pardossi-Piquard et al., 2005), p53 (Alves da Costa
et al., 2006), Fibronectin1 (FN1), α2-actin, transgelin (SM22),
tropomyosin 1 (TPM1), flavoprotein oxidoreductase MICAL2
(MICAL2), Ras-associated protein (RAB3B) (Muller et al., 2007),
EGF receptor (EGFR) (Zhang et al., 2007), LRP (LRP1) (Liu et al.,
2007), Cyclins B1 and D1 (Ahn et al., 2008), vesicular glutamate
transporter (VGLUT2) (Schrenk-Siemens et al., 2008), C/EBP
homologous protein (CHOP) (Takahashi et al., 2009), Aquaporin
1 (Huysseune et al., 2009), S100a9 (Ha et al., 2010), ApoJ/clusterin
(Kogel et al., 2012), patched homolog 1 (Ptch1), transient receptor
potential cation channel subfamily C member 5 (TRPC5) (Das
et al., 2011), serine-palmitoyl transferase (SPT) subunit SPTLC2
(Grimm et al., 2011a), alkyl-dihydroxyacetonephosphate-synthase
(AGPS) (Grimm et al., 2011b), GD3 synthase (GD3S) (Grimm
et al., 2012), Stathmin1 (Muller et al., 2013), and PGC1α (Robin-
son et al., 2013). A summary of these genes including the exper-
imental procedures to investigate a potential impact of AICD on
their expression are listed in Table 2.
The metastasis suppressor KAI1 was the first identified func-
tionally significant AICD target gene. A direct interaction of the
AFT complex with the KAI1 promoter region initiates the dis-
placement of the N-CoR/TAB2/HDAC3 corepressor complex and
leads to an increase of KAI1 mRNA and protein levels in the central
nervous system of APP transgenic mice. In these mice the protein
levels of APP, Fe65 and Tip60 are dramatically increased as well
(Baek et al., 2002). The expression of glycogen synthase kinase-3β
(GSK3β), which is implicated in the hyperphosphorylation of tau
in AD, was also shown to be upregulated by AICD. Overexpression
of AICD in PC12 cells and in rat primary cortical neurons induces
the expression of GSK3β and its promoter activity. In this study
the enhanced expression of GSK3β is followed by an increase in
tau phosphorylation and a reduction of β-catenin levels, leading to
apoptosis (Kim et al., 2003). The GSK3β mediated tau phospho-
rylation induced by AICD may provide a link between APP and
tau, the two proteins that are responsible for the major pathologic
hallmarks of AD. Von Rotz et al. (2004) confirmed the upregula-
tion of KAI1, APP, BACE1, Tip60, and GSK3β, but not Fe65, in
HEK293 cells after inducible AICD overexpression, indicating a
feed-forward mechanism, in which AICD upregulates the expres-
sion of its own precursor APP, the APP cleaving enzyme BACE1,
involved in its generation, and Tip60, involved in its signaling path-
way. The elevation of GSK3β activity by AICD was validated in vivo
in AICD transgenic mice, where it results in enhanced phospho-
rylation of CPMP2 protein, a GSK3β substrate involved in axonal
guidance (Ryan and Pimplikar, 2005). AICD is further linked to
apoptosis by the observation that the proapoptotic tumor suppres-
sor gene p53 is affected by AICD nuclear signaling. This may be an
additional explanation for the AICD induced and Tip60 depen-
dent cell death, which is abolished by p53 deficiency (Passer et al.,
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) 2000; Kinoshita et al., 2002; Ozaki et al., 2006). Genetic depletion
of APP/APLP2 or PS and reduction of γ-secretase activity leads to
decreased expression and activity of p53 and in line with this to
a reduced activation of the p53 promoter. p53 expression is also
diminished in vivo in the brains of PS- or APP-deficient mice. In
contrast, enhanced p53 activity and p53 promoter transactivation
was observed in AICD overexpressing blastocysts and HEK293
cells (Alves da Costa et al., 2006).
In contrast to the studies mentioned above, several authors
failed to observe an impact of AICD on the regulation of the
same target genes. Hébert et al. reported the protein levels of the
potential AICD target genes APP and GSK3β not to be altered
in cells treated with γ-secretase-inhibitors or in biological mod-
els genetically deficient for AICD generation. In line, analysis of
the transactivation properties of AICD on the promoter regions
of KAI1 and APP only showed modest effects (Hebert et al.,
2006). Transcriptome analysis of a human neuroblastoma cell line
inducible for expression of AICD, Fe65 or both failed to identify
differential expression of KAI1, GSK3β,APP, and NEP. In this study
real-time quantitative PCR confirmed that AICD or AICD/Fe65
expression is not associated with changes in the expression of either
KAI1 or GSK3β (Muller et al., 2007). In a study by Waldron et al.
increased AICD levels generated in the presence of NH4Cl, failed
to stimulate the APP and KAI1 promoter regions in luciferase
reporter assays. The lack of a transactivation potential of AICD on
these genes is further demonstrated by the unchanged NEP, KAI1,
BACE1, EGFR, Tip60, and p53 mRNA levels. It should be noted,
that AICD accumulating under these conditions is derived from
C83, indicating that it represents an AICD species that is discussed
not to be transcriptionally active as mentioned above (Waldron
et al., 2008).
Summary
Many conflicting data and models concerning the role of AICD in
promoting the expression of several potential AICD target genes
including NEP have emerged. This might be due to the short half-
life of AICD, which per se complicates the finding of experimental
conditions to elucidate the physiological role of AICD.
ANALYSIS OF THE IMPACT OF AICD IN GENE REGULATION:
EXPERIMENTAL CHALLENGES AND FURTHER APPROACHES
Up to now the impact of AICD in gene regulation in general
and in transcriptional regulation of NEP in particular is highly
controversially discussed. As reviewed above several controversial
findings have been published, which might be due the extraordi-
nary experimental challenges of this topic. In this paragraph we
will summarize these challenges and suitable methods to deal with
these problems, briefly explaining the advantage and disadvantage
of each method.
Addressing the role of AICD in gene regulation, the most
prominent problem to deal with is the extremely short half-life
of the peptide (Cupers et al., 2001) caused by proteolytic degra-
dation by caspases, IDE or the proteasome (Gervais et al., 1999;
Edbauer et al., 2002; Farris et al., 2003; Nunan et al., 2003). Espe-
cially the use of non-overexpressing systems or incubation of cells
with physiological concentrations of AICD results in a false neg-
ative study outcome. However, it is possible to inhibit the AICD
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degrading processes with specific inhibitors, such as MG-132 and
Epoxomicin for proteasome (Gersbacher et al., 2013) or Bacitracin
for IDE resulting in an increased half-life of AICD. Using such
inhibitors one has to be aware of the partially high cytotoxicity
and that beside AICD the degradation of a huge amount of other
proteins and peptides is also inhibited, making the conclusion
from the obtained results more ambiguous.
Alternatively, higher concentrations of AICD can be used for
incubation. However, it has to be taken into consideration that
artificial assembly of AICD with adapter proteins might be the
consequence, generating false positive results. The same prob-
lem occurs with APP overexpressing cell lines, where additionally
missorting and protein accumulation might take place. Inducible
promotors like used in TET-systems could help to overcome
these challenges. Moreover, enhancing the AICD uptake by using
lipofection reagents might be beneficial.
Beside the addition of the peptide and expressing AICD or
its precursor constructs, reasonable results could be obtained by
reducing the cellular amount of AICD. In principle APP KO, PS
KO, and BACE1 KO cells are available and often used for analysis.
Utilizing these KOs, it has to be mentioned that beside AICD the
generation of further APP cleavage products is inhibited as well,
making it impossible to differentiate between the impact of AICD
in comparison to other APP derived fragments.
Moreover, APP might accumulate due to inhibiting its catab-
olism and it has already been shown that APP itself is involved
in transcriptional regulation as summarized in the next section.
Beside the lack of other APP cleavage products and the accumu-
lation of APP, γ-secretase as well as BACE1 have several other
substrates, which are also affected by the KO, making it neces-
sary to combine different approaches and to look for intersections
of the obtained results. In addition to the false positive results
obtained by affecting other proteins and mechanisms, APP KO
models might also lead to false negative findings. As mentioned
in Section “Proteolytic Processing of APP” not only APP but the
whole APP family has AICD like domains (ALID1/2 in the case
of APLP1 and APLP2), which can be released and are potentially
transcriptionally active. It is assumed that ALID1 and ALID2 are
at least partially able to compensate the lack of AICD. Therefore it
should be considered to utilize combined APP/APLP1/APLP2-KO
cells to investigate the effects of AICD. Furthermore it has to be
pointed out that mostly, because of their ability to immortalize,
mouse embryonic fibroblasts (MEFS) are used. It has been shown
that AICD transcriptional regulation is at least in some cases tis-
sue specific. Therefore results obtained from fibroblasts cannot be
automatically transferred to other tissues like brain. To avoid these
problems knock downs of the relevant proteins in neuronal cell
lines like N2A (murine) and SH-SY5Y (human) cells or pharmaco-
logical inhibition of the secretases in these systems can be addition-
ally used. However, it has to be balanced whether the toxicity of the
inhibitors and the incomplete knock down of the proteins might
affect the obtained findings. Moreover, beside the results found
in cell culture experiments in vivo relevance has to be proofed.
Using littermates for controls helps to reduce genetical heterogene-
ity. In living organisms it cannot be ruled out that compensating
mechanisms make it more difficult to elucidate the role of a lack-
ing peptide or protein, which might also result in reduced effect
strength. On top of these problems many KO mouse models, like
PS1/2 double KO or APP/APLPL2 double KO mice, are lethal in
embryonic or early postnatal status (Wang et al., 2005a). For AICD
transcriptional regulation of proteins involved in tissue differenti-
ation are postulated (see Table 2). Especially the lethal phenotype
of mice lacking APP and APLP2 in early stages aggravates the
analysis of AICD function on gene transcription of these proteins.
In addition to the above mentioned KO systems, a truncated
APP construct expressed in absence of the whole APP family is used
in some studies (Huysseune et al., 2009; Grimm et al., 2011a,b).
The truncated APP lacks the CTF and therefore AICD. By utilizing
this system it is in principal possible to distinguish if an effect is
caused by AICD or other APP cleavage products. However, the
missing CTF also influences Aβ generation making this differen-
tiation less distinct. To avoid or circumvent this problem it might
be helpful to test if the observed phenotype could be partially
rescued by adding AICD peptide, combining the advantages and
disadvantages of both systems. Additionally the analysis of the KO
or knock down of AICD adaptor proteins like Fe65 might help to
understand the underlying mechanism, especially in combination
with other experimental approaches.
Finally, promoter analysis using, e.g., luciferase assays should
be mentioned. Utilizing this approach it is possible to investi-
gate if AICD is indeed able to affect the specific promotor regions
of potential target genes. It has to be taken into consideration
that these systems mainly use episomal vectors, making trans-
port, or transport dependent processes to the nucleus unnecessary.
This experimental approach is not suitable to distinguish between
the transcriptional impact of C83 (α-CTF) and C99 (β-CTF)
derived AICD.
As no optimal experimental approach having no disadvan-
tages is available, it has to be accepted that only the combination
of different experimental methods and models is sufficient to
unambiguously evaluate the role of AICD in gene regulation.
Summary
The combination of several genetic and/or pharmalogical
approaches is necessary to elucidate the AICD-mediated regu-
lation of potential AICD target genes. For genes found to be
regulated by AICD in cell culture systems the in vivo relevance
should be tested in animal models, and to rule out in general
an effect of AICD several tissues have to be analyzed as the gene
regulatory role of AICD seems to be tissue specific.
GENE REGULATORY FUNCTIONS OF APP INDEPENDENT OF AICD
Besides AICD, it has been reported that other APP cleavage prod-
ucts and even full length APP have an impact on gene regulation.
The secreted APP ectodomain possibly regulates downstream
target genes via binding to one or several yet unknown recep-
tor(s) activating intracellular pathways leading to altered gene
expression. sAPPα was shown to increase the expression of sev-
eral neuroprotective genes, among them transthyretin (TTR) and
insulin-like growth factor-2 (IGF-2) in mouse organotypic hip-
pocampal cultures and protects them from Aβ-induced tau phos-
phorylation and neuronal death (Stein et al., 2004). Recently, a
study by Ryan et al. (2013) confirmed such a function of sAPPα in
rat hippocampal organotypic slice cultures, where sAPPα rapidly
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elicited a multi-level transcriptional response including the regu-
lation of several transcription factors, microRNAs and the mod-
ulation of the chromatin environment. The kinase CDK5 and the
chaperone ORP150 have been also reported to be regulated by
sAPPα. Treatment of neurons with sAPPα peptide leads to reduced
expression and activity of CDK5, which is involved in the phos-
phorylation of tau and induces Aβ generation (Cruz et al., 2006;
Piedrahita et al., 2010). In contrast, the expression of the neuro-
protective chaperone ORP150 (Kitao et al., 2001; Tamatani et al.,
2001) is induced by sAPPα treatment. Importantly, these effects
could not be observed in Sorl1-deficient neurons arguing for a
role of SORLA as an essential sAPPα receptor (Hartl et al., 2013).
In APP/APLP2-deficient mice the expression of TTR, involved in
amyloid suppression (Schwarzman et al., 1994; Choi et al., 2007),
and Klotho, related to various aging processes (Kuro-o et al., 1997;
Kurosu et al., 2005) is downregulated. In contrast, an upregulation
of TTR and Klotho mRNA levels was observed in sAPPβ-knockin
mice indicating a role of the APP β-cleaved ectodomain in the
regulation of these genes (Li et al., 2010).
Independent of sAPPα, sAPPβ, and AICD generation APP
has been reported to regulate gene expression as well. Tran-
scriptional downregulation of acetylcholinesterase (AchE) by full
length APP was found in two neuronal cell lines (Hicks et al.,
2013). Additionally, APP holoprotein was reported to regulate
cholesterol metabolism at a transcriptional level. Pierrot et al.
(2013) showed the expression of APP in rat cortical neurons to
decrease both the mRNA levels of 3-hydroxy-3-methylglutaryl-
coenzym-A-reductase (HMGCR) and cholesterol 24-hydroxylase
leading to a reduction in cholesterol turnover and to inhibition
of neuronal activity. APP was further reported to downregu-
late the expression of the transcription factor EGR-1 at both
mRNA and protein levels in vivo and in cultured neurons and
in a γ-secretase-independent manner (Hendrickx et al., 2013).
Additionally, intracellular Aβ peptide is discussed to act as tran-
scription factor binding to Aβ peptide interacting domain (AβID)
sequences within the promoter regions of some genes. Ohyagi
et al. (2005) showed intracellular Aβ to directly activate the p53
promoter resulting in p53-dependent apoptosis. The transcrip-
tion factors ASCL1 and OLIG2 are also regulated in cell culture
by Aβ (Uchida, JBC, 2007). Moreover, interactions between Aβ
and sequences within the APP and BACE1 promoters have been
reported by the use of Chip assays on human neuroblastoma cells
(Bailey et al., 2011) and by electrophoretic mobility shift assays
(EMSA) indicating that Aβ peptide may regulate genes involved in
its own production (Maloney and Lahiri, 2011). However, further
studies concerning the role of APP and its cleavage products in
gene regulation are necessary.
Summary
Impact in gene regulation is not only reported for AICD, but
also for full length APP and its cleavage products sAPPα, sAPPβ,
and Aβ.
CONCLUDING REMARKS
Summing it up, several lines of evidence underline the importance
of NEP in Aβ clearance. A reduced NEP activity has been associated
with AD and increased Aβ levels. In return upregulation of NEP
FIGURE 5 | Regulation of genes involved in neuroprotection (green),
neurotoxicity (red) or other genes (orange) by AICD. On the one hand
AICD enhances (+) the expression and/or activity of APP, the β-secretase
BACE1, p53, and GSK3β leading to enhanced Aβ generation, apoptosis, and
tau phosphorylation. On the other hand AICD also induces NEP gene
expression resulting in increased Aβ degradation and reduced Aβ levels. A
regulatory cycle can be postulated, in which AICD regulates its own
production via induction of APP and BACE1 gene expression also
generating Aβ peptide, whose degradation is stimulated at the same time
via upregulation of NEP expression.
might be protective or beneficial for AD. However, the underly-
ing mechanisms of NEP regulation are controversially discussed.
One of the most favored models suggests that the amyloidogenic
APP cleavage product, AICD, which has high similarities to Notch,
is involved in the transcriptional regulation of NEP. Nevertheless
additional studies will be necessary to further clarify the role of
AICD in NEP regulation and to elucidate whether indeed NEP
upregulation is suitable to prevent or treat AD. As AICD has been
linked to the induction of genes both involved in neuroprotection
and neurotoxicity, an upregulation of AICD can not be assumed
as positive in general. On the one hand, AICD is discussed to
upregulate the expression and/or activity of APP, BACE1, p53,
and GSK3β leading to enhanced Aβ generation, apoptosis and
tau phosphorylation, all of these processes linked to neurotoxic-
ity. On the other hand, AICD induces NEP expression leading to
increased Aβ degradation resulting in lowered Aβ levels. Regarding
the therapeutic potential of an AICD upregulation further studies
are necessary to answer the question if the positive or negative
consequences of an AICD upregulation predominate. Moreover,
the site effects of an enhanced NEP level also need further investi-
gation keeping in mind the numerous substrates of NEP including
several neuropeptides.
A regulatory cycle can be postulated, in which AICD regulates
its own production via induction of APP and BACE1 gene expres-
sion with the Aβ peptide as secondary product, whose degradation
is stimulated at the same time via upregulation of NEP gene expres-
sion (summarized in Figure 5). In a pathological situation like
AD this cycle seems to be disturbed resulting in enhanced Aβ
production along with reduced NEP levels leading to the severe
accumulation of Aβ in brain tissue.
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